Trial Profile
A phase II, single arm, open label, multicentre study of CP-751,871 in combination with docetaxel and prednisone in patients with progressive hormone refractory prostate cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 May 2006
Price :
$35
*
At a glance
- Drugs Figitumumab (Primary) ; Docetaxel; Prednisone
- Indications Prostate cancer
- Focus Therapeutic Use
- 25 May 2006 New trial record.